COVID‑19 in China: From epidemiology to treatment (Review)
- Authors:
- Hongtao Chen
- Shipin Wu
- Xiaoyong Zhang
-
Affiliations: Department of Infectious Diseases, The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, Guangdong 518020, P.R. China, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China - Published online on: October 15, 2020 https://doi.org/10.3892/etm.2020.9353
- Article Number: 223
-
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al: Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 395:565–574. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Tan WJ, Zhao X, Ma XJ, Wang W, Niu P, Xu W, Gao GF and Wu G: A novel coronavirus genome identified in a cluster of pneumonia cases-Wuhan, China 2019-2020. China CDC Weekly. 2:61–62. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, et al: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579:270–273. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 5:536–544. 2020.PubMed/NCBI View Article : Google Scholar | |
|
World Health Organization (WHO): Novel coronavirus disease named COVID-19. WHO, Geneva, 2020. urihttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happensimplehttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen. Accessed February 11, 2020. | |
|
Xiang N, Havers F, Chen T, Song Y, Tu W, Li L, Cao Y, Liu B, Zhou L, Meng L, et al: Use of national pneumonia surveillance to describe influenza A(H7N9) virus epidemiology, China, 2004-2013. Emerg Infect Dis. 19:1784–1790. 2013.PubMed/NCBI View Article : Google Scholar | |
|
European Centre for Disease Prevention and Control: Risk assessment: Outbreak of acute respiratory syndrome associated with a novel coronavirus, Wuhan, China. urihttps://www.ecdc.europa.eu/sites/default/files/documents/Risk-assessment-pneumonia-Wuhan-China-22-Jan-2020.pdfsimplehttps://www.ecdc.europa.eu/sites/default/files/documents/Risk-assessment-pneumonia-Wuhan-China-22-Jan-2020.pdf. Accessed January 22, 2020. | |
|
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al: A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 382:727–733. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Cohen E: Super spreaders in coronavirus outbreaks. CNN health, 2020. urihttps://edition.cnn.com/2020/01/23/health/wuhan-virus-super-spreader/index.htmlsimplehttps://edition.cnn.com/2020/01/23/health/wuhan-virus-super-spreader/index.html. Accessed January 23, 2020. | |
|
China Centre for Disease Prevention and Control: Distribution of COVID-19 outbreaks. urihttp://2019ncov.chinacdc.cn/2019-nCoVsimplehttp://2019ncov.chinacdc.cn/2019-nCoV. | |
|
Chutian Metropolis Daily: Central steering group: Over 60,000 beds were completed in wuhan in one month, equivalent to the construction of 60 tertiary hospitals. urihttp://news.cnhubei.com/content/2020-03/06/content_12823832.htmlsimplehttp://news.cnhubei.com/content/2020-03/06/content_12823832.html. Accessed March 6, 2020. | |
|
Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, Jiang YZ, Xiong Y, Li YJ, Li XW, et al: Identification of a novel coronavirus causing severe pneumonia in human: A descriptive study. Chin Med J (Engl). 133:1015–1024. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, Zhong W and Hao P: Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 63:457–460. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L and Wang X: Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 581:215–220. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A and Li F: Structural basis of receptor recognition by SARS-CoV-2. Nature. 581:221–224. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181:271–280.e278. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen KY, et al: Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 181:894–904.e9. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Ji W, Wang W, Zhao X, Zai J and Li X: Cross-species transmission of the newly identified coronavirus 2019-nCoV. J Med Virol. 92:433–440. 2020.PubMed/NCBI View Article : Google Scholar | |
|
South China Agricultural University: Press conference of scientific research on novel coronavirus pneumonia outbreak. Guangzhou, 7 February, 2020. | |
|
Tang XL, Wu CC, Li X, Song YH, Yao XM, Wu XK, Duan YG, Zhang H, Wng YR, Qian ZH, et al: On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev. 7:1012–1023. 2020. | |
|
Khiali S, Khani E and Entezari-Maleki T: A comprehensive review on tocilizumab in COVID-19 acute respiratory distress syndrome. J Clin Pharmacol: June 18, 2020 (Epub ahead of print). | |
|
Tay MZ, Poh CM, Rénia L, MacAry PA and Ng LEP: The trinity of COVID-19: Immunity, inflammation and intervention. Nat Rev Immunol. 20:363–374. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Vardhana S and Wolchok J: The many faces of the anti-COVID immune response. J Exp Med. 217(e20200678)2020.PubMed/NCBI View Article : Google Scholar | |
|
Lew TW, Kwek TK, Tai D, Earnest A, Loo S, Singh K, Kwan KM, Chan Y, Yim CF, Bek SL, et al: Acute respiratory distress syndrome in critically Ill patients with severe acute respiratory syndrome. JAMA. 290:374–380. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Drosten C, Seilmaier M, Corman VM, Hartmann W, Scheible G, Sack S, Guggemos W, Kallies R, Muth D, Junglen S, et al: Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis. 13:745–751. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Moore B and June C: Cytokine release syndrome in severe COVID-19. Science. 368:473–474. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, Sun R, Tian Z, Xu X and Wei H: Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci Rev. 7:998–1002. 2020. | |
|
Lang F, Lee K, Teijaro J, Becher B and Hamilton J: GM-CSF-based treatments in COVID-19: Reconciling opposing therapeutic approaches. Nat Rev Immunol. 20:507–514. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 395:497–506. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Blanco-Melo D, Nilsson-Payant B, Liu WC, Uhl S, Hoagland D, Møller R, Jordan T, Oishi K, Panis M, Sachs D, et al: Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 181:1036–1045.e9. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Park A and Iwasaki A: Type I and Type III interferons-induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe. 27:870–878. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, Liu L, Shan H, Lei C, Hui DSC, et al: Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 382:1708–1720. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Cao X: COVID-19: Immunopathology and its implications for therapy. Nat Rev Immunol. 20:269–270. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Chen X, Ling J, Mo P, Zhang Y, Jiang Q, Ma Z, Cao Q, Hu W, Zou S, Chen L, et al: Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients. medRxiv: urihttps://doi.org/10.1101/2020.03.03.20030437simplehttps://doi.org/10.1101/2020.03.03.20030437. | |
|
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, et al: Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 8:420–422. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Tian S, Hu W, Niu L, Liu H, Xu H and Xiao SY: Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 15:700–704. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Luo W, Yu H, Gou J, Li X, Sun Y, Li J and Liu L: Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19): Pulmonary fibrosis and vascular changes including microthrombosis formation. Preprint: doi: 10.13140/RG.2.2.22934.29762. | |
|
General Office of National Health Commission: Diagnosis and treatment of novel coronavirus pneumonia (trial version seventh) (In Chinese). urihttp://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/ce3e6945832a438eaae415350a8ce964.pdfsimplehttp://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/ce3e6945832a438eaae415350a8ce964.pdf. | |
|
Carsana L, Sonzogni A, Nasr A, Rossi R, Pellegrinelli A, Zerbi P, Rech R, Colombo R, Antinori S, Corbellino M, et al: Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: A two-centre descriptive study. Lancet Infect Dis. 20:1135–1140. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Deshmukh V, Motwani D, Kumar A, Kumari C and Raza K: Histopathological observations in COVID-19: A systematic review. J Clin Pathol: Aug 18, 2020 (Epub ahead of print). | |
|
Docherty A, Harrison E, Green C, Hardwick H, Pius R, Norman L, Holden K, Read J, Dondelinger F, Carson G, et al: Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: Prospective observational cohort study. BMJ. 369(m1985)2020.PubMed/NCBI View Article : Google Scholar | |
|
Li L, Li R, Wu Z, Yang X, Zhao M, Liu J and Chen D: Therapeutic strategies for critically ill patients with COVID-19. Ann Intensive Care. 10(45)2020.PubMed/NCBI View Article : Google Scholar | |
|
The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)-China, 2020. China CDC Weekly. 2:113–122. 2020.PubMed/NCBI View Article : Google Scholar | |
|
China National Medical Products Administration: Novel Coronavirus detection product is subject to emergency approval by the China National Medical Products Administration. urihttps://www.nmpa.gov.cn/zhuanti/yqyjzxd/yqyjxd/20200316153801928.htmlsimplehttps://www.nmpa.gov.cn/zhuanti/yqyjzxd/yqyjxd/20200316153801928.html. Accessed March 16, 2020. | |
|
Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y and Zheng C: Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. Lancet Infect Dis. 20:425–434. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Dong D, Tang Z, Wang S, Hui H, Gong L, Lu Y, Xue Z, Liao H, Chen F, Yang F, et al: The role of imaging in the detection and management of COVID-19: A review. IEEE Rev Biomed Eng: Apr 27, 2020 (Epub ahead of print). | |
|
Dai W, Zhang H, Yu J, Xu H, Chen H, Luo S, Zhang H, Liang L, Wu X, Lei Y, et al: CT imaging and differential diagnosis of COVID-19. Can Assoc Radiol J. 71:195–200. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Wang N, Zhan Y, Zhu L, Hou Z, Liu F, Song P, Qiu F, Wang X, Zou X, Wan D, et al: Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients. Cell Host Microbe. 28:455–464.e2. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Balfour HH Jr: Antiviral drugs. N Engl J Med. 340:1255–1268. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Bergman SJ, Ferguson MC and Santanello C: Interferons as therapeutic agents for infectious diseases. Infect Dis Clin North Am. 25:819–834. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Rüther U, Stilz S, Röhl E, Nunnensiek C, Rassweiler J, Dörr U and Jipp P: Successful interferone-alpha 2 a therapy for a patient with acute mumps orchitis. Eur Urol. 27:174–176. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Hayden FG, Kaiser DL and Albrecht JK: Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds. Antimicrob Agents Chemother. 32:224–230. 1988.PubMed/NCBI View Article : Google Scholar | |
|
Grennan D: Mumps. JAMA. 322(1022)2019.PubMed/NCBI View Article : Google Scholar | |
|
Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, Pham DH, Deif H, LaMere EA, Chang M, et al: Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndromea preliminary study. JAMA. 290:3222–3228. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W, Yin Z, Huang S, Deng Z, Wei M, et al: Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol. 52:715–720. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Stockman LJ, Bellamy R and Garner P: SARS: Systematic review of treatment effects. PLoS Med. 3(e343)2006.PubMed/NCBI View Article : Google Scholar | |
|
Peng F, Tu L, Yang Y, Hu P, Wang R, Hu Q, Cao F, Jiang T, Sun J, Xu G and Chang C: Management and treatment of COVID-19: The Chinese experience. Can J Cardiol. 36:915–930. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Chen F, Chan KH, Jiang Y, Kao RY, Lu HT, Fan KW, Cheng VC, Tsui WH, Hung IF, Lee TS, et al: In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. 31:69–75. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 395:507–513. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, et al: A Trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 382:1787–1799. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Gordon CJ, Tchesnokov EP, Feng JY, Porter DP and Götte M: The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 295:4773–4779. 2020.PubMed/NCBI View Article : Google Scholar | |
|
de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, Scott D, Cihlar T and Feldmann H: Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA. 117:6771–6776. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Agostini M, Andres E, Sims A, Graham R, Sheahan T, Lu X, Smith E, Case J, Feng J, Jordan R, et al: Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 9:e00221–18. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, et al: Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 9(eaal3653)2017.PubMed/NCBI View Article : Google Scholar | |
|
Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, et al: First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 382:929–936. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, et al: Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 382:2327–2336. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, et al: Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 395:1569–1578. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Beigel JH, Tomashek KM and Dodd LE: Remdesivir for the treatment of Covid-19-preliminary report. N Engl J Med. 383(994)2020.PubMed/NCBI View Article : Google Scholar | |
|
Coomes EA and Haghbayan H: Favipiravir, an antiviral for COVID-19? J Antimicrob Chemother. 75:2013–2014. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Jacobs M, Aarons E, Bhagani S, Buchanan R, Cropley I, Hopkins S, Lester R, Martin D, Marshall N, Mepham S, et al: Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: A case-series of health-care workers. Lancet Infect Dis. 15:1300–1304. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Bai CQ, Mu JS, Kargbo D, Song YB, Niu WK, Nie WM, Kanu A, Liu WW, Wang YP, Dafae F, et al: Clinical and virological characteristics of ebola virus disease patients treated with favipiravir (T-705)-Sierra Leone, 2014. Clin Infect Dis. 63:1288–1294. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Sissoko D, Laouenan C, Folkesson E, M'Lebing A-B, Beavogui A-H, Baize S, Camara A-M, Maes P, Shepherd S, Danel C, et al: Experimental treatment with favipiravir for ebola virus disease (the JIKI trial): A historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 13(e1001967)2016.PubMed/NCBI View Article : Google Scholar | |
|
Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y, et al: Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering (Beijing): Mar 18, 2020. (Epub ahead of print). | |
|
Rainsford KD, Parke AL, Clifford-Rashotte M and Kean WF: Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 23:231–269. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Keyaerts E, Vijgen L, Maes P, Neyts J and Van Ranst M: In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 323:264–268. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W and Xiao G: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30:269–271. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, et al: In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 71:732–739. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W and Wang M: Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery. 6(16)2020.PubMed/NCBI View Article : Google Scholar | |
|
Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 43:185–188. 2020.PubMed/NCBI View Article : Google Scholar : (In Chinese). | |
|
Kupferschmidt K: Big studies dim hopes for hydroxychloroquine. Science. 368:1166–1167. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E, et al: Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial. BMJ. 369(m1849)2020.PubMed/NCBI View Article : Google Scholar | |
|
Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, Labella A, Manson DK, Kubin C, Barr RG, et al: Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 382:2411–2418. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, Weinberg P, Kirkwood J, Muse A, DeHovitz J, et al: Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA. 323:2493–2502. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, Skipper CP, Nascene AA, Nicol MR, Abassi M, et al: A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 383:517–525. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Fadel R, Morrison Austin R, Vahia A, Smith ZR, Chaudhry Z, Bhargava P, Miller J, Kenney RM, Alangaden G and Ramesh MS: Henry Ford COVID-19 Management Task Force: Early short course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis: May 19, 2020 (Epub ahead of print). | |
|
Shang L, Zhao J, Hu Y, Du R and Cao B: On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 395:683–684. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Yazdanpanah F, Hamblin MR and Rezaei N: The immune system and COVID-19: Friend or foe? Life Sciences. 256(117900)2020.PubMed/NCBI View Article : Google Scholar | |
|
Kolilekas L, Loverdos K, Giannakaki S, Vlassi L, Levounets A, Zervas E and Gaga M: Can steroids reverse the severe COVID-19 induced ‘cytokine storm’? J Med Virol: Jun 12, 2020 (Epub ahead of print). | |
|
Taboada M, Caruezo V, Naveira A and Atanassoff PG: Corticosteroids and the hyper-inflammatory phase of the COVID-19 disease. J Clin Anesth. 66(109926)2020.PubMed/NCBI View Article : Google Scholar | |
|
Russell CD, Millar JE and Baillie JK: Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 395:473–475. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Li H, Chen C, Hu F, Wang J, Zhao Q, Gale RP and Liang Y: Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: A systematic review and meta-analysis. Leukemia. 34:1503–1511. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Zha L, Li S, Pan L, Tefsen B, Li Y, French N, Chen L, Yang G and Villanueva EV: Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 212:416–420. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Chen RC, Tang XP, Tan SY, Liang BL, Wan Z, Fang JQ and Zhong N: Treatment of severe acute respiratory syndrome with glucosteroids. Chest. 129:1441–1452. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Li H, Yang S, Gu L, Zhang Y, Yan X, Liang Z, Zhang W, Jia H, Chen W, Liu M, et al: Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia. Influenza Other Respir Viruses. 11:345–354. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, Aguilar G, Alba F, González-Higueras E, Conesa LA, et al: Dexamethasone treatment for the acute respiratory distress syndrome: A multicentre, randomised controlled trial. Lancet Respir Med. 8:267–276. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Zhao JP, Hu Y, Du RH, Chen ZS, Jin Y, Zhou M, J Z, Qu JM and B C: Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 43(E007)2020.PubMed/NCBI View Article : Google Scholar : (In Chinese). | |
|
Gimeno J, Mestres-Truyol J, Ojeda-Montes MJ, Macip G, Saldivar-Espinoza B, Cereto-Massagué A, Pujadas G and Garcia-Vallvé S: Prediction of novel inhibitors of the main protease (M-pro) of SARS-CoV-2 through consensus Docking and drug reposition. Int J Mol Sci. 21(3793)2020.PubMed/NCBI View Article : Google Scholar | |
|
Burmester GR, Feist E, Sleeman MA, Wang B, White B and Magrini F: Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: A randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann Rheum Dis. 70:1542–1549. 2011.PubMed/NCBI View Article : Google Scholar | |
|
De Luca G, Cavalli G, Campochiaro C, Della-Torre E, Angelillo P, Tomelleri A, Boffini N, Tentori S, Mette F, Farina N, et al: GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: A single-centre, prospective cohort study. Lancet Rheumatol. 2:e465–e473. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Vijayvargiya P, Esquer Garrigos Z, Castillo Almeida NE, Gurram PR, Stevens RW and Razonable RR: Treatment considerations for COVID-19: A critical review of the evidence (or Lack Thereof). Mayo Clin Proc. 95:1454–1466. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Temesgen Z, Assi M, Shweta FNU, Vergidis P, Rizza SA, Bauer PR, Pickering BW, Razonable RR, Libertin CR, Burger CD, et al: GM-CSF neutralization with lenzilumab in severe COVID-19 pneumonia: A case-control study. Mayo Clin Proc, 2020. | |
|
Temesgen Z, Assi M, Vergidis P, Rizza SA, Bauer PR, Pickering BW, Razonable RR, Libertin CR, Burger CD, Orenstein R, et al: First clinical use of lenzilumab to neutralize GM-CSF in patients with severe COVID-19 pneumonia. medRxiv 2020.2006.2008.20125369, 2020. | |
|
Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-O'Callaghan A, Pardos-Gea J, Quintana A, Mekinian A, Anunciacion-Llunell A and Miró-Mur F: Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. Autoimmun Rev. 19(102569)2020.PubMed/NCBI View Article : Google Scholar | |
|
Garbers C, Heink S, Korn T and Rose-John S: Interleukin-6: Designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov. 17:395–412. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Pfäfflin A and Schleicher E: Inflammation markers in point-of-care testing (POCT). Anal Bioanal Chem. 393:1473–1480. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Bloos F and Reinhart K: Rapid diagnosis of sepsis. Virulence. 5:154–160. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Ma L, Zhang H, Yin Y, Guo W, Ma Y, Wang Y, Shu C and Dong L: Role of interleukin-6 to differentiate sepsis from non-infectious systemic inflammatory response syndrome. Cytokine. 88:126–135. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, et al: Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 117:10970–10975. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, et al: Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 376:652–662. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Bronte V, Ugel S, Tinazzi E, Vella A, De Sanctis F, Canè S, Batani V, Trovato R, Fiore A, Petrova V, et al: Baricitinib restrains the immune dysregulation in severe COVID-19 patients. J Clin Invest: 141772, 2020. Doi: 10.1172/JCI141772. (Online ahead of print). | |
|
Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D and Richardson P: COVID-19: Combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 20:400–402. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Jorgensen SCJ, Ly Tse C, Burry L and Dresser LD: Baricitinib: A review of pharmacology, safety and emerging clinical experience in COVID-19. Pharmacotherapy. 40:843–856. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Rawling M, Savory E and Stebbing J: Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 395:e30–e31. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P and Goletti D: Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 81:318–356. 2020.PubMed/NCBI View Article : Google Scholar | |
|
National Institute of Allergy and Infectious Diseases: Adaptive COVID-19 Treatment Trial 2. urihttp://ClinicalTrials.govsimpleClinicalTrials.gov Identifier: NCT04401579. urihttps://clinicaltrials.gov/ct2/show/NCT04401579?cond=ACTT-2&draw=2&rank=1simplehttps://clinicaltrials.gov/ct2/show/NCT04401579?cond=ACTT-2&draw=2&rank=1. Last Updated August 13, 2020. | |
|
National Institute of Allergy and Infectious Diseases: Adaptive COVID-19 treatment trial (ACTT). urihttp://ClinicalTrials.govsimpleClinicalTrials.gov Identifier: NCT04280705. urihttps://clinicaltrials.gov/ct2/show/study/NCT04280705simplehttps://clinicaltrials.gov/ct2/show/study/NCT04280705. | |
|
Wu R, Wang L, Kuo HD, Shannar A, Peter R, Chou PJ, Li S, Hudlikar R, Liu X, Liu Z, et al: An update on current therapeutic drugs treating COVID-19. Curr Pharmacol. Rep:1–15. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Roback JD and Guarner J: Convalescent plasma to treat COVID-19: Possibilities and challenges. JAMA. 323:1561–1562. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, et al: Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 323:1582–1589. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Xia X, Li K, Wu L, Wang Z, Zhu M, Huang B, Li J, Wang Z, Wu W, Wu M, et al: Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion. Blood. 136:755–759. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Hegerova L, Gooley TA, Sweerus KA, Maree C, Bailey N, Bailey M, Dunleavy V, Patel K, Alcorn K, Haley R, et al: Use of convalescent plasma in hospitalized patients with Covid-19: Case series. Blood. 136:759–762. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, et al: Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 117:9490–9496. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, Kong Y, Ren L, Wei Q, Mei H, et al: Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial. JAMA. 324:460–470. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Sharpe HR, Gilbride C, Allen E, Belij-Rammerstorfer S, Bissett C, Ewer K and Lambe T: The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world. Immunology. 160:223–232. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Callaway E: The race for coronavirus vaccines: A graphical guide. Nature. 580:576–577. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, et al: Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 369:77–81. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, et al: Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 182:713–721.e9. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, et al: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 395:1845–1854. 2020.PubMed/NCBI View Article : Google Scholar |
